• Nanjing Leads Biolabs outlined six studies accepted for presentation at the 2026 ESMO meeting in Madrid on Oct. 23-27.
• Two studies won top-tier oral slots, signaling clinically meaningful activity across hard-to-treat solid tumors without new safety signals disclosed.
• Four additional studies will be shown as posters, expanding visibility for its immuno-oncology pipeline in indications such as biliary tract cancer.
• A late-breaking abstract slot was granted, with a full submission planned for September 2026, pointing to a potentially practice-relevant update.
• Separately, LBL-024 was slated for an oral presentation at WCLC in September 2026, with an abstract due Aug. 19, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260713-12242264), on July 13, 2026, and is solely responsible for the information contained therein.